Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study-Reference-Cited by-同舟云学术

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

Published:2011-04 Issue:4 Volume:12 Page:361-368
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ansell Stephen M,Tang Hui,Kurtin Paul J,Koenig Patricia A,Inwards David J,Shah Keith,Ziesmer Steven C,Feldman Andrew L,Rao Radha,Gupta Mamta,Erlichman Charles,Witzig Thomas E

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Mantle cell lymphoma: a clinicopathologic study of 80 cases;Argatoff;Blood,1997

2. Mantle-cell lymphoma: a population-based clinical study;Velders;J Clin Oncol,1996

3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project;Blood,1997

4. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004;Zhou;Cancer,2008

5. Mantle cell lymphoma—does primary intensive immunochemotherapy improve overall survival for younger patients?;Geisler;Leuk Lymphoma,2009

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells;Frontiers in Immunology;2024-04-04

2. Macrolides for Cancer;Progress in Inflammation Research;2024

3. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects;International Journal of Molecular Sciences;2023-09-14

4. Clinical Experiences with Drugs Targeting m TOR;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

5. Mantelzelllymphom;Indolente Lymphome;2023